TABLE 2.
Genetic group distribution of viruses sequenced among study sites participating in the random sequencing of influenza positive specimens. I‐MOVE primary care multicentre case control study, influenza season 2021–2022
| Clade | n | % | |
|---|---|---|---|
| Total influenza A(H1N1)pdm09 a | n = 153 | ||
| Sequenced b | 53 | 35 | |
| A/Guangdong‐Maonan/SWL1536/2019‐like | 6B.1A.5a.1 | 53 | 100 |
| Total influenza A(H3N2) a | N = 1354 | ||
| Sequenced b | 410 | 30 | |
| A/Bangladesh/4005/2020‐like | 3C.2a1b.2a.2 | 402 | 98 |
| No subgroup | 1 | <1 | |
| New subgroup c | 63 | 15 | |
| Subgroup (i) | 1 | <1 | |
| Subgroup (iii) | 64 | 16 | |
| Subgroup (iv) | 273 | 68 | |
| A/Denmark/3264/2019 | 3C.2a1b.1a | 8 | 2 |
a
Among study sites and labs providing data from sequencing (countries included: DE, ES, FR, IE, NA, NL, PT, SE; two labs in FR not included).
b
Among patients included in the pooled analysis after restrictions.
c
Harbouring E50K, F79V, I140K mutations.